Role of nebulized amphotericin B in the management of allergic bronchopulmonary aspergillosis in cystic fibrosis: Case report and review of literature.
OBJECTIVE
To review the data available in literature about nebulized amphotericin B (AMB) in the treatment of allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis (CF) and to report our experience in the use of this drug, with a particular therapeutic scheme.


METHODS
We used nebulized liposomal amphotericin B (L-AMB) in a patient affected by CF, complicated by ABPA. The previous combined treatment with oral steroids and azoles had no respiratory benefit and caused relevant side effects. Amphotericin B has always been well tolerated and permitted a slight steroid tapering. We also observed benefits in pulmonary function and laboratory tests.


CONCLUSIONS
Few data are available in literature about the use of nebulized AMB in CF and there are no RCTs evaluating antifungals in CF-ABPA. In our opinion, the reported case suggests that nebulized L-AMB could represent a possible strategy in ABPA management in CF patients.
Rosaria
R
Casciaro
Aldo
A
Naselli
Federico
F
Cresta
Mirco
M
Ros
Elio
E
Castagnola
Laura
L
Minicucci
D000328:Adult; D000666:Amphotericin B / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000627:therapeutic use*; D001229:Aspergillosis, Allergic Bronchopulmonary / Q000188:drug therapy* / Q000382:microbiology; D001232:Aspergillus fumigatus / Q000187:drug effects*; D003550:Cystic Fibrosis / Q000150:complications*; D019468:Disease Management; D006801:Humans; D008297:Male; D055815:Young Adult
D000935:Antifungal Agents; C068538:liposomal amphotericin B; D000666:Amphotericin B
Amphotericin B,; Antifungal therapy,; Aspergillosis,; Azole antifungals; Cystic fibrosis,